Adrenocortical Carcinoma

Mansmann, 2004, The clinically inapparent adrenal mass: update in diagnosis and management, Endocr Rev, 25, 309, 10.1210/er.2002-0031

Viani, 2009, Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials, Int J Radiat Oncol Biol Phys, 74, 1405, 10.1016/j.ijrobp.2008.10.091

Allolio, 2006, Clinical review: Adrenocortical carcinoma: clinical update, J Clin Endocrinol Metab, 91, 2027, 10.1210/jc.2005-2639

Kebebew, 2006, Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?, World J Surg, 30, 872, 10.1007/s00268-005-0329-x

Pianovski, 2006, Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil, Pediatr Blood Cancer, 47, 56, 10.1002/pbc.20624

Figueiredo, 2006, Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation, J Med Genet, 43, 91, 10.1136/jmg.2004.030551

Garritano, 2010, Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect, Hum Mutat, 31, 143, 10.1002/humu.21151

Pinto, 2004, Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors, Arq Bras Endocrinol Metabol, 48, 647, 10.1590/S0004-27302004000500009

Fassnacht, 2009, Clinical management of adrenocortical carcinoma, Best Pract Res Clin Endocrinol Metab, 23, 273, 10.1016/j.beem.2008.10.008

Luton, 1990, Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy, N Engl J Med, 322, 1195, 10.1056/NEJM199004263221705

Bilimoria, 2008, Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors, Cancer, 113, 3130, 10.1002/cncr.23886

Wajchenberg, 2000, Adrenocortical carcinoma: clinical and laboratory observations, Cancer, 88, 711, 10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W

Wooten, 1993, Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature, Cancer, 72, 3145, 10.1002/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N

Wasserman, 2012, Towards an understanding of the role of p53 in adrenocortical carcinogenesis, Mol Cell Endocrinol, 351, 101, 10.1016/j.mce.2011.09.010

Schteingart, 2005, Management of patients with adrenal cancer: recommendations of an international consensus conference, Endocr Relat Cancer, 12, 667, 10.1677/erc.1.01029

Crucitti, 1996, The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group, Surgery, 119, 161, 10.1016/S0039-6060(96)80164-4

Michalkiewicz, 2004, Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry, J Clin Oncol, 22, 838, 10.1200/JCO.2004.08.085

Hsing, 1996, Risk factors for adrenal cancer: an exploratory study, Int J Cancer, 65, 432, 10.1002/(SICI)1097-0215(19960208)65:4<432::AID-IJC6>3.0.CO;2-Y

Icard, 2001, Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group, World J Surg, 25, 891, 10.1007/s00268-001-0047-y

Sirianni, 2012, Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment, J Clin Endocrinol Metab, 97, E2238, 10.1210/jc.2012-2374

Kerber, 2005, A cohort study of cancer risk in relation to family histories of cancer in the Utah population database, Cancer, 103, 1906, 10.1002/cncr.20989

Dong, 2001, Modification of cancer risks in offspring by sibling and parental cancers from 2,112,616 nuclear families, Int J Cancer, 92, 144, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1147>3.0.CO;2-C

Fraumeni, 1967, Adrenocortical neoplasms with hemihypertrophy, brain tumors, and other disorders, J Pediatr, 70, 129, 10.1016/S0022-3476(67)80179-3

Nader, 1983, Adrenal cortical carcinoma. A study of 77 cases, Cancer, 52, 707, 10.1002/1097-0142(19830815)52:4<707::AID-CNCR2820520424>3.0.CO;2-N

Fassnacht, 2010, Epidemiology of adrenocortical carcinoma, Adrenocortical Carcinoma, 1st ed, 23

Venkatesh, 1989, Adrenal cortical carcinoma, Cancer, 64, 765, 10.1002/1097-0142(19890801)64:3<765::AID-CNCR2820640333>3.0.CO;2-I

Lima Lde, 2011, Clinical and molecular aspects of a pediatric metachronous adrenocortical tumor, Arq Bras Endocrinol Metabol, 55, 72, 10.1590/S0004-27302011000100010

Rodriguez-Galindo, 2005, Biology, clinical characteristics, and management of adrenocortical tumors in children, Pediatr Blood Cancer, 45, 265, 10.1002/pbc.20318

Varley, 1999, Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors, Am J Hum Genet, 65, 995, 10.1086/302575

Wagner, 1994, High frequency of germline p53 mutations in childhood adrenocortical cancer, J Natl Cancer Inst, 86, 1707, 10.1093/jnci/86.22.1707

Li, 1988, A cancer family syndrome in twenty-four kindreds, Cancer Res, 48, 5358

Bougeard, 2008, Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families, J Med Genet, 45, 535, 10.1136/jmg.2008.057570

Chompret, 2001, Sensitivity and predictive value of criteria for p53 germline mutation screening, J Med Genet, 38, 43, 10.1136/jmg.38.1.43

Chompret, 2000, P53 germline mutations in childhood cancers and cancer risk for carrier individuals, Br J Cancer, 82, 1932

Herrmann, 2012, TP53 germline mutations in adult patients with adrenocortical carcinoma, J Clin Endocrinol Metab, 97, E476, 10.1210/jc.2011-1982

Raymond, 2013, Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma, J Clin Endocrinol Metab, 98, E119, 10.1210/jc.2012-2198

Custódio, 2012, Molecular epidemiology of adrenocortical tumors in southern Brazil, Mol Cell Endocrinol, 351, 44, 10.1016/j.mce.2011.10.019

Latronico, 2001, An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors, J Clin Endocrinol Metab, 86, 4970, 10.1210/jcem.86.10.7957

Ribeiro, 2001, An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma, Proc Natl Acad Sci U S A, 98, 9330, 10.1073/pnas.161479898

Custódio, 2013, Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors, J Clin Oncol, 31, 2619, 10.1200/JCO.2012.46.3711

Weksberg, 2005, Beckwith-Wiedemann syndrome, Am J Med Genet C Semin Med Genet, 137C, 12, 10.1002/ajmg.c.30058

Beckwith, Extreme cytomegaly of the adrenal fetal cortex, omphalocele, hyperplasia of kidneys and pancreas, and Leydig-cell hyperplasia: another syndrome?

Lapunzina, 2005, Risk of tumorigenesis in overgrowth syndromes: a comprehensive review, Am J Med Genet C Semin Med Genet, 137C, 53, 10.1002/ajmg.c.30064

Wiedemann, 1983, Tumours and hemihypertrophy associated with Wiedemann-Beckwith syndrome, Eur J Pediatr, 141, 129, 10.1007/BF00496807

Gibril, 2004, Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature, Medicine (Baltimore), 83, 43, 10.1097/01.md.0000112297.72510.32

Skogseid, 1995, Adrenal lesion in multiple endocrine neoplasia type 1, Surgery, 118, 1077, 10.1016/S0039-6060(05)80117-5

Waldmann, 2007, Adrenal involvement in multiple endocrine neoplasia type 1: results of 7 years prospective screening, Langenbecks Arch Surg, 392, 437, 10.1007/s00423-006-0124-7

Gatta-Cherifi, 2012, Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database, Eur J Endocrinol, 166, 269, 10.1530/EJE-11-0679

Griniatsos, 2011, Bilateral adrenocortical carcinoma in a patient with multiple endocrine neoplasia type 1 (MEN1) and a novel mutation in the MEN1 gene, World J Surg Oncol, 9, 6, 10.1186/1477-7819-9-6

Langer, 2002, Adrenal involvement in multiple endocrine neoplasia type 1, World J Surg, 26, 891, 10.1007/s00268-002-6492-4

Skogseid, 1992, Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1, J Clin Endocrinol Metab, 75, 76

Thakker, 2012, Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1), J Clin Endocrinol Metab, 97, 2990, 10.1210/jc.2012-1230

Karamurzin, 2012, Unusual DNA mismatch repair-deficient tumors in Lynch syndrome: a report of new cases and review of the literature, Hum Pathol, 43, 1677, 10.1016/j.humpath.2011.12.012

Medina-Arana, 2011, Adrenocortical carcinoma, an unusual extracolonic tumor associated with Lynch II syndrome, Fam Cancer, 10, 265, 10.1007/s10689-010-9416-8

Berends, 2000, Adrenocortical adenocarcinoma in an MSH2 carrier: coincidence or causal relation?, Hum Pathol, 31, 1522, 10.1053/hupa.2000.20409

Broaddus, 2004, Unusual tumors associated with the hereditary nonpolyposis colorectal cancer syndrome, Mod Pathol, 17, 981, 10.1038/modpathol.3800150

Stoffel, 2009, Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome, Gastroenterology, 137, 1621, 10.1053/j.gastro.2009.07.039

Weissman, 2012, Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline, J Genetic Couns, 21, 484, 10.1007/s10897-011-9465-7

Hampel, 2005, Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer), N Engl J Med, 352, 1851, 10.1056/NEJMoa043146

Dinh, 2011, Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population, Cancer Prev Res, 4, 9, 10.1158/1940-6207.CAPR-10-0262

Järvinen, 2000, Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer, Gastroenterology, 118, 829, 10.1016/S0016-5085(00)70168-5

Raymond, 2013, Adrenocortical carcinoma is a Lynch syndrome-associated cancer, J Clin Oncol, 31, 3012, 10.1200/JCO.2012.48.0988

Takazawa, 2004, Unusual double primary neoplasia: adrenocortical and ureteral carcinomas in werner syndrome, Urol Int, 72, 168, 10.1159/000075974

Seki, 1992, Loss of normal allele of the APC gene in an adrenocortical carcinoma from a patient with familial adenomatous polyposis, Hum Genet, 89, 298, 10.1007/BF00220544

Wakatsuki, 1998, Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associated with a complete inactivating mutation of the APC gene and unusual histological features, Hum Pathol, 29, 302, 10.1016/S0046-8177(98)90052-1

Painter, 1985, Adrenal adenomas and adrenal carcinomas in association with hereditary adenomatosis of the colon and rectum, Cancer, 55, 2001, 10.1002/1097-0142(19850501)55:9<2001::AID-CNCR2820550929>3.0.CO;2-7

Fienman, 1970, Neurofibromatosis in childhood, J Pediatr, 76, 339, 10.1016/S0022-3476(70)80472-3

Sørensen, 1986, Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms, N Engl J Med, 314, 1010, 10.1056/NEJM198604173141603

Else, 2010, Overview of genetic syndromes associated with adrenocortical cancer, Adrenocortical Carcinoma, 1st ed, 153

Marshall, 1967, Gardner's syndrome with adrenal carcinoma, Australas Ann Med, 16, 242, 10.1111/imj.1967.16.3.242

Traill, 1995, Adrenal carcinoma in a patient with Gardner's syndrome: imaging findings, AJR Am J Roentgenol, 165, 1460, 10.2214/ajr.165.6.7484586

Wagner, 2005, Pediatric adrenal cortical carcinoma: brain metastases and relationship to NF-1, case reports and review of the literature, J Neurooncol, 75, 127, 10.1007/s11060-005-0376-z

Anselmo, 2012, A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer, J Clin Endocrinol Metab, 97, 351, 10.1210/jc.2011-2244

Morin, 2012, Carney complex with adrenal cortical carcinoma, J Clin Endocrinol Metab, 97, E202, 10.1210/jc.2011-2321

Bauman, 1982, Virilizing adrenocortical carcinoma. Development in a patient with salt-losing congenital adrenal hyperplasia, JAMA, 248, 3140, 10.1001/jama.1982.03330230052032

Barzon, 2007, The role of 21-hydroxylase in the pathogenesis of adrenal masses: review of the literature and focus on our own experience, J Endocrinol Invest, 30, 615, 10.1007/BF03346358

Nermoen, 2011, High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency, Clin Endocrinol (Oxf), 75, 753, 10.1111/j.1365-2265.2011.04151.x

NIH

Ishikura, 2010, Cushing's syndrome and big IGF-II associated hypoglycaemia in a patient with adrenocortical carcinoma, BMJ Case Rep, 2010, 10.1136/bcr.07.2009.2100

Anderson, 1930, A tumor of the adrenal gland with fatal hypoglycemia, Am J Med Sci, 180, 71, 10.1097/00000441-193007000-00009

Rustin, 1983, Adrenocortical carcinoma with tumour-induced hypoglycaemia, J R Soc Med, 76, 74, 10.1177/014107688307600116

Yamanaka, 2000, A case of renin-producing adrenocortical cancer, Endocr J, 47, 119, 10.1507/endocrj.47.119

Oka, 1996, Erythropoietin-producing adrenocortical carcinoma, Urol Int, 56, 246, 10.1159/000282852

Schteingart, 2001, Overexpression of CXC chemokines by an adrenocortical carcinoma: a novel clinical syndrome, J Clin Endocrinol Metab, 86, 3968, 10.1210/jcem.86.8.7780

Abiven, 2006, Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients, J Clin Endocrinol Metab, 91, 2650, 10.1210/jc.2005-2730

Seccia, 2005, Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course, Endocr Relat Cancer, 12, 149, 10.1677/erc.1.00867

Egoshi, 1998, 11-Deoxycorticosterone-producing adrenocortical carcinoma, Urol Int, 61, 251, 10.1159/000030341

Müssig, 2005, Adrenocortical carcinoma producing 11-deoxycorticosterone: a rare cause of mineralocorticoid hypertension, J Endocrinol Invest, 28, 61, 10.1007/BF03345531

Sturgeon, 2006, Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy?, J Am Coll Surg, 202, 423, 10.1016/j.jamcollsurg.2005.11.005

Paton, 2006, Outcomes of adrenal cortical carcinoma in the United States, Surgery, 140, 914, 10.1016/j.surg.2006.07.035

Fassnacht, 2009, Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification, Cancer, 115, 243, 10.1002/cncr.24030

Allolio, 2004, Management of adrenocortical carcinoma, Clin Endocrinol (Oxf), 60, 273, 10.1046/j.1365-2265.2003.01881.x

Nieman, 2008, The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab, 93, 1526, 10.1210/jc.2008-0125

Grondal, 1990, Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma, Acta Endocrinol (Copenh), 122, 656, 10.1530/acta.0.1220656

Arlt, 2011, Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors, J Clin Endocrinol Metab, 96, 3775, 10.1210/jc.2011-1565

Song, 2011, Risk of catecholamine crisis in patients undergoing resection of unsuspected pheochromocytoma, Int Braz J Urol, 37, 35, 10.1590/S1677-55382011000100005

Johnson, 2009, Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls, Radiographics, 29, 1333, 10.1148/rg.295095027

Bharwani, 2011, Adrenocortical carcinoma: the range of appearances on CT and MRI, AJR Am J Roentgenol, 196, W706, 10.2214/AJR.10.5540

Dunnick, 1982, CT appearance of adrenal cortical carcinoma, J Comput Assist Tomogr, 6, 978, 10.1097/00004728-198210000-00020

Berland, 2010, Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee, J Am Coll Radiol, 7, 754, 10.1016/j.jacr.2010.06.013

Hussain, 1985, Differentiation of malignant from benign adrenal masses: predictive indices on computed tomography, AJR Am J Roentgenol, 144, 61, 10.2214/ajr.144.1.61

Haider, 2004, Chemical shift MR imaging of hyperattenuating (&gt;10 HU) adrenal masses: does it still have a role?, Radiology, 231, 711, 10.1148/radiol.2313030676

Caoili, 2000, Delayed enhanced CT of lipid-poor adrenal adenomas, AJR Am J Roentgenol, 175, 1411, 10.2214/ajr.175.5.1751411

Slattery, 2006, Adrenocortical carcinoma: contrast washout characteristics on CT, AJR Am J Roentgenol, 187, W21, 10.2214/AJR.04.1751

Elsayes, 2004, Adrenal masses: MR imaging features with pathologic correlation, Radiographics, 24, S73, 10.1148/rg.24si045514

Fishman, 1987, Primary adrenocortical carcinoma: CT evaluation with clinical correlation, AJR Am J Roentgenol, 148, 531, 10.2214/ajr.148.3.531

Egbert, 2010, Computed tomography of adrenocortical carcinoma containing macroscopic fat, Cancer Imaging, 10, 198, 10.1102/1470-7330.2010.0029

Groussin, 2009, 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients, J Clin Endocrinol Metab, 94, 1713, 10.1210/jc.2008-2302

Sundin, 2012, Imaging of adrenal masses with emphasis on adrenocortical tumors, Theranostics, 2, 516, 10.7150/thno.3613

Hahner, 2008, [123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes, J Clin Endocrinol Metab, 93, 2358, 10.1210/jc.2008-0050

Mackie, 2006, Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma, J Clin Endocrinol Metab, 91, 2665, 10.1210/jc.2005-2612

Leboulleux, 2006, Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography, J Clin Endocrinol Metab, 91, 920, 10.1210/jc.2005-1540

Khan, 2003, 11C-Metomidate PET imaging of adrenocortical cancer, Eur J Nucl Med Mol Imaging, 30, 403, 10.1007/s00259-002-1025-9

Terzolo, 2011, AME position statement on adrenal incidentaloma, Eur J Endocrinol, 164, 851, 10.1530/EJE-10-1147

Funder, 2008, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 93, 3266, 10.1210/jc.2008-0104

Mantero, 2000, A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology, J Clin Endocrinol Metab, 85, 637

Song, 2008, The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy, AJR Am J Roentgenol, 190, 1163, 10.2214/AJR.07.2799

Zhang, 2006, Imaging of primary adrenal lymphoma: case report and literature review, Acta Radiol, 47, 993, 10.1080/02841850600885393

Hough, 1979, Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data, Am J Clin Pathol, 72, 390, 10.1093/ajcp/72.3.390

van Slooten, 1985, Morphologic characteristics of benign and malignant adrenocortical tumors, Cancer, 55, 766, 10.1002/1097-0142(19850215)55:4<766::AID-CNCR2820550414>3.0.CO;2-7

Weiss, 1984, Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors, Am J Surg Pathol, 8, 163, 10.1097/00000478-198403000-00001

Aubert, 2002, Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors, Am J Surg Pathol, 26, 1612, 10.1097/00000478-200212000-00009

Giordano, 2010, Adrenocortical tumors: an integrated clinical, pathologic, and molecular approach at the University of Michigan, Arch Pathol Lab Med, 134, 1440, 10.5858/2010-0320-RA.1

Volante, 2009, Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification, Histopathology, 55, 535, 10.1111/j.1365-2559.2009.03423.x

Papotti, 2011, The Weiss score and beyond–histopathology for adrenocortical carcinoma, Horm Cancer, 2, 333, 10.1007/s12672-011-0088-0

Cibas, 1990, Cellular DNA profiles of benign and malignant adrenocortical tumors, Am J Surg Pathol, 14, 948, 10.1097/00000478-199010000-00008

Arola, 2000, p53 and Ki67 in adrenocortical tumors, Endocr Res, 26, 861, 10.3109/07435800009048609

Sasano, 1995, Cell proliferation and apoptosis in normal and pathologic human adrenal, Mod Pathol, 8, 11

Morimoto, 2008, Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas, Endocr J, 55, 49, 10.1507/endocrj.K07-079

Giordano, 2011, The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma, Am J Surg Pathol, 35, 471, 10.1097/PAS.0b013e31820bcf21

Zhang, 2008, Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical tumors: immunohistochemical analysis of adrenocortical tumors, Appl Immunohistochem Mol Morphol, 16, 32, 10.1097/PAI.0b013e318032cf56

Arola, 2000, Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the neoplasm, J Endocrinol, 165, 223, 10.1677/joe.0.1650223

Arola, 1998, Expression of inhibin alpha in the human adrenal gland and adrenocortical tumors, Endocr Res, 24, 865, 10.3109/07435809809032699

Jorda, 2002, Calretinin and inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas, Appl Immunohistochem Mol Morphol, 10, 67, 10.1097/00129039-200203000-00012

Schröder, 1992, Immunocytochemistry in adrenocortical tumours: a clinicomorphological study of 72 neoplasms, Virchows Arch A Pathol Anat Histopathol, 420, 65, 10.1007/BF01605986

Ghorab, 2003, Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas, Appl Immunohistochem Mol Morphol, 11, 330, 10.1097/00129039-200312000-00009

Sbiera, 2010, High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors, J Clin Endocrinol Metab, 95, E161, 10.1210/jc.2010-0653

Duregon, 2013, Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates, Hum Pathol, 44, 822, 10.1016/j.humpath.2012.07.025

Weiss, 1989, Pathologic features of prognostic significance in adrenocortical carcinoma, Am J Surg Pathol, 13, 202, 10.1097/00000478-198903000-00004

Ohgaki, 1993, p53 mutations in sporadic adrenocortical tumors, Int J Cancer, 54, 408, 10.1002/ijc.2910540310

Lin, 1994, Mutations of the p53 gene in human functional adrenal neoplasms, J Clin Endocrinol Metab, 78, 483

Reincke, 1994, p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies, J Clin Endocrinol Metab, 78, 790

Heaton, 2012, Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin, Am J Pathol, 181, 1017, 10.1016/j.ajpath.2012.05.026

Berthon, 2012, Wnt/β-catenin signalling in adrenal physiology and tumour development, Mol Cell Endocrinol, 351, 87, 10.1016/j.mce.2011.09.009

Leal, 2011, Wnt/β-catenin pathway deregulation in childhood adrenocortical tumors, J Clin Endocrinol Metab, 96, 3106, 10.1210/jc.2011-0363

Gaujoux, 2011, β-Catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma, Clin Cancer Res, 17, 328, 10.1158/1078-0432.CCR-10-2006

El Wakil, 2011, The Wnt/β-catenin pathway in adrenocortical development and cancer, Mol Cell Endocrinol, 332, 32, 10.1016/j.mce.2010.11.014

Masi, 2009, Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors, J Endocrinol Invest, 32, 597, 10.1007/BF03346515

Tissier, 2005, Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors, Cancer Res, 65, 7622, 10.1158/0008-5472.CAN-05-0593

Assie, 2012, Gene expression profiling in adrenocortical neoplasia, Mol Cell Endocrinol, 351, 111, 10.1016/j.mce.2011.09.044

Ribeiro, 2000, Adrenocortical tumors in children, Braz J Med Biol Res, 33, 1225, 10.1590/S0100-879X2000001000013

Cagle, 1986, Comparison of adrenal cortical tumors in children and adults, Cancer, 57, 2235, 10.1002/1097-0142(19860601)57:11<2235::AID-CNCR2820571127>3.0.CO;2-O

Dehner, 2009, Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?, Pediatr Dev Pathol, 12, 284, 10.2350/08-06-0489.1

Wieneke, 2003, Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients, Am J Surg Pathol, 27, 867, 10.1097/00000478-200307000-00001

Magro, 2012, Pediatric adrenocortical tumors: morphological diagnostic criteria and immunohistochemical expression of matrix metalloproteinase type 2 and human leucocyte-associated antigen (HLA) class II antigens. Results from the Italian Pediatric Rare Tumor (TREP) Study project, Hum Pathol, 43, 31, 10.1016/j.humpath.2011.04.016

West, 2007, Gene expression profiling of childhood adrenocortical tumors, Cancer Res, 67, 600, 10.1158/0008-5472.CAN-06-3767

Faria, 2012, Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults, Mol Cell Endocrinol, 351, 52, 10.1016/j.mce.2011.09.040

Erlandson, 1991, Oncocytic adrenal cortical adenoma, Ultrastruct Pathol, 15, 539, 10.3109/01913129109016261

Macchi, 1998, Adrenocortical oncocytoma: case report and review of the literature, Tumori, 84, 403, 10.1177/030089169808400318

Hoang, 2002, Oncocytic adrenocortical carcinoma: a morphologic, immunohistochemical and ultrastructural study of four cases, Mod Pathol, 15, 973, 10.1038/modpathol.3880638

Song, 2004, Oncocytic adrenocortical carcinomas: a pathological and immunohistochemical study of four cases in comparison with conventional adrenocortical carcinomas, Pathol Int, 54, 603, 10.1111/j.1440-1827.2004.01669.x

Ohtake, 2010, Oncocytic adrenocortical carcinoma, Ann Diagn Pathol, 14, 204, 10.1016/j.anndiagpath.2009.06.006

Wong, 2011, Oncocytic adrenocortical neoplasms–a clinicopathologic study of 13 new cases emphasizing the importance of their recognition, Hum Pathol, 42, 489, 10.1016/j.humpath.2010.08.010

Lin, 1998, Oncocytic adrenocortical neoplasms: a report of seven cases and review of the literature, Am J Surg Pathol, 22, 603, 10.1097/00000478-199805000-00012

Bisceglia, 2004, Adrenocortical oncocytic tumors: report of 10 cases and review of the literature, Int J Surg Pathol, 12, 231, 10.1177/106689690401200304

Brown, 2000, Myxoid neoplasms of the adrenal cortex: a rare histologic variant, Am J Surg Pathol, 24, 396, 10.1097/00000478-200003000-00008

Suresh, 2005, Myxoid adrenal cortical carcinoma–a rare variant of adrenocortical carcinoma, Indian J Med Sci, 59, 505, 10.4103/0019-5359.18970

Karim, 2006, Myxoid variant of adrenocortical carcinoma: report of a unique case, Pathol Int, 56, 89, 10.1111/j.1440-1827.2006.01929.x

Raparia, 2008, Myxoid adrenal cortical neoplasms, Ann Diagn Pathol, 12, 344, 10.1016/j.anndiagpath.2008.04.002

Papotti, 2010, Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behavior, Am J Surg Pathol, 34, 973, 10.1097/PAS.0b013e3181e2b726

Hsieh, 2011, Myxoid adrenal cortical carcinoma presenting as primary hyperaldosteronism: case report and review of the literature, Int J Surg Pathol, 19, 803, 10.1177/1066896909356925

Zhang, 2011, Myxoid adrenocortical neoplasms: a study of the clinicopathologic features and EGFR gene status of ten Chinese cases, Am J Clin Pathol, 136, 783, 10.1309/AJCP7LO3NAYQKASZ

Sheng, 2012, Myxoid adrenal cortical tumor: report of four cases, Chin Med J (Engl), 125, 1672

Giordano, 2003, Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis, Am J Pathol, 162, 521, 10.1016/S0002-9440(10)63846-1

Coli, 2010, Sarcomatoid carcinoma of the adrenal gland: a case report and review of literature, Pathol Res Pract, 206, 59, 10.1016/j.prp.2009.02.012

Ragazzon, 2011, Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments, Endocrine-related cancer, 18, R15

Beuschlein, 1994, Clonal composition of human adrenocortical neoplasms, Cancer Res, 54, 4927

Gicquel, 1994, Clonal analysis of human adrenocortical carcinomas and secreting adenomas, Clin Endocrinol (Oxf), 40, 465, 10.1111/j.1365-2265.1994.tb02485.x

Blanes, 2006, DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions, Hum Pathol, 37, 1295, 10.1016/j.humpath.2006.04.025

Klein, 1985, Flow cytometric determinations of ploidy and proliferation patterns of adrenal neoplasms: an adjunct to histological classification, J Urol, 134, 862, 10.1016/S0022-5347(17)47495-7

Bowlby, 1986, Flow cytometric analysis of adrenal cortical tumor DNA. Relationship between cellular DNA and histopathologic classification, Cancer, 58, 1499, 10.1002/1097-0142(19861001)58:7<1499::AID-CNCR2820580721>3.0.CO;2-V

Amberson, 1987, Flow cytometric determination of nuclear DNA content in benign adrenal pheochromocytomas, Urology, 30, 102, 10.1016/0090-4295(87)90171-3

Kjellman, 1996, Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy, Cancer Res, 56, 4219

Gicquel, 2001, Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors, Cancer Res, 61, 6762

Kjellman, 1999, Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16, J Clin Endocrinol Metab, 84, 730

Zhao, 1999, Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis, Am J Pathol, 155, 1039, 10.1016/S0002-9440(10)65205-4

Dohna, 2000, Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications, Genes Chromosomes Cancer, 28, 145, 10.1002/(SICI)1098-2264(200006)28:2<145::AID-GCC3>3.0.CO;2-7

Barreau, 2013, Identification of a CpG Island Methylator Phenotype in Adrenocortical Carcinomas, J Clin Endocrinol Metab, 98, E174, 10.1210/jc.2012-2993

Stephan, 2008, Adrenocortical carcinoma survival rates correlated to genomic copy number variants, Mol Cancer Ther, 7, 425, 10.1158/1535-7163.MCT-07-0267

de Fraipont, 2005, Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy, J Clin Endocrinol Metab, 90, 1819, 10.1210/jc.2004-1075

de Reyniès, 2009, Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival, J Clin Oncol, 27, 1108, 10.1200/JCO.2008.18.5678

Giordano, 2009, Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling, Clin Cancer Res, 15, 668, 10.1158/1078-0432.CCR-08-1067

Fragoso, 2012, Combined expression of BUB1B, DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in a Brazilian cohort of adult and pediatric patients, Eur J Endocrinol, 166, 61, 10.1530/EJE-11-0806

Czech, 2011, Small RNA sorting: matchmaking for Argonautes, Nat Rev Genet, 12, 19, 10.1038/nrg2916

Cimmino, 2005, miR-15 and miR-16 induce apoptosis by targeting BCL2, Proc Natl Acad Sci U S A, 102, 13944, 10.1073/pnas.0506654102

Lujambio, 2012, The microcosmos of cancer, Nature, 482, 347, 10.1038/nature10888

Tömböl, 2009, Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis, Endocr Relat Cancer, 16, 895, 10.1677/ERC-09-0096

Soon, 2009, miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer, Clin Cancer Res, 15, 7684, 10.1158/1078-0432.CCR-09-1587

Doghman, 2010, Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors, Cancer Res, 70, 4666, 10.1158/0008-5472.CAN-09-3970

Patterson, 2011, MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy, Cancer, 117, 1630, 10.1002/cncr.25724

Veronese, 2010, Oncogenic role of miR-483-3p at the IGF2/483 locus, Cancer Res, 70, 3140, 10.1158/0008-5472.CAN-09-4456

Barzon, 2001, Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors, Eur J Endocrinol, 145, 207, 10.1530/eje.0.1450207

Gicquel, 1997, Molecular markers for malignancy in adrenocortical tumors, Horm Res, 47, 269, 10.1159/000185475

Nobori, 1994, Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers, Nature, 368, 753, 10.1038/368753a0

Pilon, 1999, Inactivation of the p16 tumor suppressor gene in adrenocortical tumors, J Clin Endocrinol Metab, 84, 2776

Gaujoux, 2008, Wnt/β-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic β-catenin gene mutations in the progression of adrenocortical tumors, J Clin Endocrinol Metab, 93, 4135, 10.1210/jc.2008-0631

Tadjine, 2008, Detection of somatic β-catenin mutations in primary pigmented nodular adrenocortical disease (PPNAD), Clin Endocrinol (Oxf), 69, 367, 10.1111/j.1365-2265.2008.03273.x

Tadjine, 2008, Frequent mutations of β-catenin gene in sporadic secreting adrenocortical adenomas, Clin Endocrinol (Oxf), 68, 264, 10.1111/j.1365-2265.2007.03033.x

Samani, 2007, The role of the IGF system in cancer growth and metastasis: overview and recent insights, Endocr Rev, 28, 20, 10.1210/er.2006-0001

Voutilainen, 1987, Coordinate tropic hormone regulation of mRNAs for insulin-like growth factor II and the cholesterol side-chain-cleavage enzyme, P450scc [corrected], in human steroidogenic tissues, Proc Natl Acad Sci U S A, 84, 1590, 10.1073/pnas.84.6.1590

l'Allemand, 1996, Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells, J Clin Endocrinol Metab, 81, 3892

Pham-Huu-Trung, 1991, Effects of insulin-like growth factor I (IGF-I) on enzymatic activity in human adrenocortical cells. Interactions with ACTH, J Steroid Biochem Mol Biol, 39, 903, 10.1016/0960-0760(91)90348-9

Mesiano, 1997, Developmental and functional biology of the primate fetal adrenal cortex, Endocr Rev, 18, 378

Han, 1992, Insulin-like growth factor-II (IGF-II) messenger ribonucleic acid is expressed in steroidogenic cells of the developing ovine adrenal gland: evidence of an autocrine/paracrine role for IGF-II, Endocrinology, 131, 3100, 10.1210/endo.131.6.1446644

Gaston, 2001, Analysis of the methylation status of the KCNQ1OT and H19 genes in leukocyte DNA for the diagnosis and prognosis of Beckwith-Wiedemann syndrome, Eur J Hum Genet, 9, 409, 10.1038/sj.ejhg.5200649

DeChiara, 1991, Parental imprinting of the mouse insulin-like growth factor II gene, Cell, 64, 849, 10.1016/0092-8674(91)90513-X

Hao, 1993, Tumour-suppressor activity of H19 RNA, Nature, 365, 764, 10.1038/365764a0

Ilvesmäki, 1993, Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas, J Clin Endocrinol Metab, 77, 852

De Fraipont, 2002, Transcription profiling of benign and malignant adrenal tumors by cDNA macro-array analysis, Endocr Res, 28, 785, 10.1081/ERC-120017073

Erickson, 2001, Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms, Endocr Pathol, 12, 429, 10.1385/EP:12:4:429

Logié, 1999, Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line, 23, 23

Weber, 2000, The role of the insulin-like growth factor system in adrenocortical tumourigenesis, Eur J Clin Invest, 30, 69, 10.1046/j.1365-2362.2000.0300s3069.x

Almeida, 2008, Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors, J Clin Endocrinol Metab, 93, 3524, 10.1210/jc.2008-0065

Wolf, 1994, Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth, Endocrinology, 135, 1877, 10.1210/endo.135.5.7525257

Cecim, 1991, Elevated corticosterone levels in transgenic mice expressing human or bovine growth hormone genes, Neuroendocrinology, 53, 313, 10.1159/000125734

Libé, 2005, Molecular genetics of adrenocortical tumours, from familial to sporadic diseases, Eur J Endocrinol, 153, 477, 10.1530/eje.1.02004

Barlaskar, 2009, Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma, J Clin Endocrinol Metab, 94, 204, 10.1210/jc.2008-1456

Kim, 2008, Targeted disruption of β-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex, Development, 135, 2593, 10.1242/dev.021493

Kinzler, 1991, Identification of FAP locus genes from chromosome 5q21, Science, 253, 661, 10.1126/science.1651562

Groden, 1991, Identification and characterization of the familial adenomatous polyposis coli gene, Cell, 66, 589, 10.1016/0092-8674(81)90021-0

Chapman, 2011, Identification of genetic alterations of AXIN2 gene in adrenocortical tumors, J Clin Endocrinol Metab, 96, E1477, 10.1210/jc.2010-2987

Ragazzon, 2010, Transcriptome analysis reveals that p53 and β-catenin alterations occur in a group of aggressive adrenocortical cancers, Cancer Res, 70, 8276, 10.1158/0008-5472.CAN-10-2014

Drelon, 2012, Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models, PLoS One, 7, e44171, 10.1371/journal.pone.0044171

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9

Affara, 2004, Vascular endothelial growth factor as a survival factor in tumor-associated angiogenesis, In Vivo, 18, 525

Bagri, 2010, Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale, Trends Mol Med, 16, 122, 10.1016/j.molmed.2010.01.004

de Fraipont, 2000, Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: correlation with genotypic alterations, J Clin Endocrinol Metab, 85, 4734

Kolomecki, 2001, Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours, Endocr Regul, 35, 9

Wortmann, 2010, Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma, Eur J Endocrinol, 162, 349, 10.1530/EJE-09-0804

Mariniello, 2012, Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models, Endocr Relat Cancer, 19, 527, 10.1530/ERC-11-0337

Terzolo, 2012, Management of adjuvant mitotane therapy following resection of adrenal cancer, Endocrine, 42, 521, 10.1007/s12020-012-9719-7

Hermsen, 2008, Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma, Eur J Endocrinol, 158, 911, 10.1530/EJE-07-0723

Assié, 2007, Prognostic parameters of metastatic adrenocortical carcinoma, J Clin Endocrinol Metab, 92, 148, 10.1210/jc.2006-0706

Gonzalez, 2007, Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma, Surgery, 142, 867, 10.1016/j.surg.2007.09.006

Miller, 2010, Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade, Langenbecks Arch Surg, 395, 955, 10.1007/s00423-010-0698-y

Miller, 2012, Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy, Surgery, 152, 1150, 10.1016/j.surg.2012.08.024

Sabolch, 2011, Adjuvant and definitive radiotherapy for adrenocortical carcinoma, Int J Radiat Oncol Biol Phys, 80, 1477, 10.1016/j.ijrobp.2010.04.030

Gaujoux, 2012, Recommendation for standardized surgical management of primary adrenocortical carcinoma, Surgery, 152, 123, 10.1016/j.surg.2011.09.030

Reibetanz, 2012, Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma, Ann Surg, 255, 363, 10.1097/SLA.0b013e3182367ac3

Zafar, 2008, Robot-assisted laparoscopic adrenalectomy for adrenocortical carcinoma: initial report and review of the literature, J Endourol, 22, 985, 10.1089/end.2007.0308

Gonzalez, 2005, Laparoscopic resection of adrenal cortical carcinoma: a cautionary note, Surgery, 138, 1078, 10.1016/j.surg.2005.09.012

Guerrieri, 2008, The learning curve in laparoscopic adrenalectomy, J Endocrinol Invest, 31, 531, 10.1007/BF03346403

Park, 2009, Outcomes from 3144 adrenalectomies in the United States: which matters more, surgeon volume or specialty?, Arch Surg, 144, 1060, 10.1001/archsurg.2009.191

Zeiger, 2009, American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations, Endocr Pract, 15, 450, 10.4158/EP.15.5.450

Berruti, 2012, Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, vii131, 10.1093/annonc/mds231

Henry, 2012, Positional statement of the European Society of Endocrine Surgeons (ESES) on malignant adrenal tumors, Langenbecks Arch Surg, 397, 145, 10.1007/s00423-011-0893-5

Grubbs, 2010, Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane, Ann Surg Oncol, 17, 263, 10.1245/s10434-009-0716-x

Leboulleux, 2010, Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?, Eur J Endocrinol, 162, 1147, 10.1530/EJE-09-1096

Lombardi, 2012, Open versus endoscopic adrenalectomy in the treatment of localized (stage I/II) adrenocortical carcinoma: results of a multiinstitutional Italian survey, Surgery, 152, 1158, 10.1016/j.surg.2012.08.014

Porpiglia, 2001, Transperitoneal laparoscopic adrenalectomy: experience in 72 procedures, J Endourol, 15, 275, 10.1089/089277901750161755

Brix, 2010, Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients, Eur Urol, 58, 609, 10.1016/j.eururo.2010.06.024

Miller, 2010, Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma, World J Surg, 34, 1380, 10.1007/s00268-010-0532-2

Castillo, 2008, Laparoscopic adrenalectomy for adrenal masses: does size matter?, Urology, 71, 1138, 10.1016/j.urology.2007.12.019

Palazzo, 2006, Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors, World J Surg, 30, 893, 10.1007/s00268-005-0288-2

Erdogan, 2013, The role of surgery in the management of recurrent adrenocortical carcinoma, J Clin Endocrinol Metab, 98, 181, 10.1210/jc.2012-2559

Schulick, 1999, Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma, Ann Surg Oncol, 6, 719, 10.1007/s10434-999-0719-7

Bellantone, 1997, Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma, Surgery, 122, 1212, 10.1016/S0039-6060(97)90229-4

Jensen, 1991, Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy, Arch Surg, 126, 457, 10.1001/archsurg.1991.01410280059008

Haak, 1994, Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients, Br J Cancer, 69, 947, 10.1038/bjc.1994.183

Icard, 1992, Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery, Surgery, 112, 972

Kendrick, 2001, Adrenocortical carcinoma: surgical progress or status quo?, Arch Surg, 136, 543, 10.1001/archsurg.136.5.543

Didolkar, 1981, Natural history of adrenal cortical carcinoma: a clinicopathologic study of 42 patients, Cancer, 47, 2153, 10.1002/1097-0142(19810501)47:9<2153::AID-CNCR2820470908>3.0.CO;2-6

Zografos, 1994, Adrenal adenocarcinoma: a review of 53 cases, J Surg Oncol, 55, 160, 10.1002/jso.2930550306

Henley, 1983, Adrenal cortical carcinoma–a continuing challenge, Surgery, 94, 926

Pommier, 1992, An eleven-year experience with adrenocortical carcinoma, Surgery, 112, 963

Nelson, 1948, Adrenal cortical atrophy and liver damage produced in dogs by feeding 2,2-bis-(parachloro-phenyl)-1,1-dichloroethane, Fed Proc, 7, 277

Sheehan, 1953, D.D.D. therapy in Cushing's syndrome, Lancet, 1, 312, 10.1016/S0140-6736(53)90992-1

Bergenstal, 1960, Chemotherapy of adrenocortical cancer with o,p'DDD, Ann Intern Med, 53, 672, 10.7326/0003-4819-53-4-672

Asp, 2010, Chiral effects in adrenocorticolytic action of o,p'-DDD (mitotane) in human adrenal cells, Xenobiotica, 40, 177, 10.3109/00498250903470230

Schteingart, 2012, Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer, Anticancer Res, 32, 2711

Lund, 1988, Metabolic activation and toxicity of a DDT-metabolite, 3-methylsulphonyl-DDE, in the adrenal zona fasciculata in mice, Chem Biol Interact, 65, 25, 10.1016/0009-2797(88)90028-2

Lindhe, 2010, Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer, Horm Metab Res, 42, 725, 10.1055/s-0030-1261923

Schteingart, 1993, Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma, Cancer Chemother Pharmacol, 31, 459, 10.1007/BF00685036

Martz, 1980, Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p,'-DDD). Correlation between adrenocorticolytic activity and metabolic activation by adrenocortical mitochondria, Drug Metab Dispos, 8, 127

Sinsheimer, 1987, Mitotane (1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane) metabolism in perfusion studies with dog adrenal glands, Drug Metab Dispos, 15, 267

Cai, 1997, Adrenal proteins bound by a reactive intermediate of mitotane, Cancer Chemother Pharmacol, 39, 537, 10.1007/s002800050610

Lindhe, 2002, Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis, J Clin Endocrinol Metab, 87, 1319

Terzolo, 2010, Mitotane, Adrenocortical Carcinoma, 1st ed, 369

Efficacy of adjuvant mitotane treatment in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence submitted to radical resection. Adiuvo website. http://www.adiuvo-trial.org.

Terzolo, 2007, Adjuvant mitotane treatment for adrenocortical carcinoma, N Engl J Med, 356, 2372, 10.1056/NEJMoa063360

Bertherat, 2007, Adjuvant mitotane in adrenocortical carcinoma, N Engl J Med, 357, 1256, 10.1056/NEJMc076267

Cerquetti, 2008, Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines, Endocr Relat Cancer, 15, 623, 10.1677/erc.1.1315

Cerquetti, 2010, Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation, Int J Oncol, 37, 493

Boven, 1984, Complete response of metastasized adrenal cortical carcinoma with o,p'-DDD. Case report and literature review, Cancer, 53, 26, 10.1002/1097-0142(19840101)53:1<26::AID-CNCR2820530107>3.0.CO;2-I

Terzolo, 2013, Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection, Eur J Endocrinol, 169, 263, 10.1530/EJE-13-0242

Hermsen, 2011, Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study, J Clin Endocrinol Metab, 96, 1844, 10.1210/jc.2010-2676

Dickstein, 1998, Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?, J Clin Endocrinol Metab, 83, 3100

Volante, 2012, Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer, Clin Cancer Res, 18, 3452, 10.1158/1078-0432.CCR-11-2692

Chortis, 2013, Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement, J Clin Endocrinol Metab, 98, 161, 10.1210/jc.2012-2851

Zatelli, 2010, Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model, Endocrinology, 151, 2453, 10.1210/en.2009-1404

Kroiss, 2011, Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma, Clin Endocrinol (Oxf), 75, 585, 10.1111/j.1365-2265.2011.04214.x

van Erp, 2011, Mitotane has a strong and a durable inducing effect on CYP3A4 activity, Eur J Endocrinol, 164, 621, 10.1530/EJE-10-0956

van Herwaarden, 2007, Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism, J Clin Invest, 117, 3583, 10.1172/JCI33435

Kroiss, 2012, Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial, J Clin Endocrinol Metab, 97, 3495, 10.1210/jc.2012-1419

Baszko-Błaszyk, 2011, Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report, Endokrynologia Polska, 62, 186

Coonrod, 1995, Virilizing adrenal carcinoma in a woman of reproductive age: a case presentation and literature review, Am J Obstet Gynecol, 172, 1912, 10.1016/0002-9378(95)91431-5

Kojori, 2011, Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure, J Pediatr Endocrinol Metab, 24, 203, 10.1515/jpem.2011.123

Leiba, 1989, The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo, Ann Endocrinol, 50, 49

Tripto-Shkolnik, 2013, Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature, J Clin Endocrinol Metab, 98, 443, 10.1210/jc.2012-2839

Feuillan, 1987, Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey, J Clin Endocrinol Metab, 65, 153, 10.1210/jcem-65-1-153

Kaplan, 1987, Lack of response to suramin in patients with AIDS and AIDS-related complex, Am J Med, 82, 615, 10.1016/0002-9343(87)90108-2

Arlt, 1994, Suramin in adrenocortical cancer: limited efficacy and serious toxicity, Clin Endocrinol (Oxf), 41, 299, 10.1111/j.1365-2265.1994.tb02549.x

LaRocca, 1991, Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation, Urol Clin North Am, 18, 123, 10.1016/S0094-0143(21)01399-9

Flack, 1993, Oral gossypol in the treatment of metastatic adrenal cancer, J Clin Endocrinol Metab, 76, 1019

Arnaldez, 2012, Targeting the insulin growth factor receptor 1, Hematol Oncol Clin North Am, 26, 527, 10.1016/j.hoc.2012.01.004

Haluska, 2010, Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma, Cancer Chemother Pharmacol, 65, 765, 10.1007/s00280-009-1083-9

Naing, 2012, Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors, Clin Cancer Res, 18, 2625, 10.1158/1078-0432.CCR-12-0061

Drelon, 2013, Adrenocortical cancer and IGF2: is the game over or our experimental models limited?, J Clin Endocrinol Metab, 98, 505, 10.1210/jc.2012-3310

Hahner, 2012, [131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma, J Clin Endocrinol Metab, 97, 914, 10.1210/jc.2011-2765

Auchus, 2010, Pharmacotherapy for hormone excess in adrenocortical carcinoma, Adrenocortical Carcinoma, 1st ed, 383

Hartzband, 1988, Assessment of hypothalamic-pituitary-adrenal (HPA) axis dysfunction: comparison of ACTH stimulation, insulin-hypoglycemia and metyrapone, J Endocrinol Invest, 11, 769, 10.1007/BF03350221

Santen, 1977, Adrenal suppression with aminoglutethimide. I. Differential effects of aminoglutethimide on glucocorticoid metabolism as a rationale for use of hydrocortisone, J Clin Endocrinol Metab, 45, 469, 10.1210/jcem-45-3-469

Schteingart, 1967, Effects of aminoglutethimide upon adrenal function and cortisol metabolism in Cushing's syndrome, J Clin Endocrinol Metab, 27, 1657, 10.1210/jcem-27-12-1657

Drake, 1998, Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis, J Clin Endocrinol Metab, 83, 3542

Schulte, 1990, Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects, J Clin Endocrinol Metab, 70, 1426, 10.1210/jcem-70-5-1426

Fleseriu, 2012, Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome, J Clin Endocrinol Metab, 97, 2039, 10.1210/jc.2011-3350

Hajjar, 1975, Adrenal cortical carcinoma. A study of 32 patients, Cancer, 35, 549, 10.1002/1097-0142(197502)35:2<549::AID-CNCR2820350239>3.0.CO;2-G

Hutter, 1966, Adrenal cortical carcinoma. Clinical features of 138 patients, Am J Med, 41, 572, 10.1016/0002-9343(66)90219-1

Huvos, 1970, Adrenal cortical carcinoma. Clinicopathologic study of 34 cases, Cancer, 25, 354, 10.1002/1097-0142(197002)25:2<354::AID-CNCR2820250212>3.0.CO;2-T

Macfarlane, 1958, Cancer of the adrenal cortex; the natural hisotry, prognosis, and treatment in a study of 55 cases, Ann R Coll Surg Engl, 23, 155

Murphy, 1967, Radiation Therapy, 2nd ed

Fassnacht, 2006, Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma, J Clin Endocrinol Metab, 91, 4501, 10.1210/jc.2006-1007

Hermsen, 2010, Response to radiation therapy in adrenocortical carcinoma, J Endocrinol Invest, 33, 712, 10.1007/BF03346675

Markoe, 1991, Radiation therapy for adjunctive treatment of adrenal cortical carcinoma, Am J Clin Oncol, 14, 170, 10.1097/00000421-199104000-00015

Percarpio, 1976, Radiation therapy of adrenal cortical carcinoma, Acta Radiol Ther Phys Biol, 15, 288, 10.3109/02841867609131965

Polat, 2009, Radiotherapy in adrenocortical carcinoma, Cancer, 115, 2816, 10.1002/cncr.24331

Magee, 1987, Adrenal cortical carcinoma: survival after radiotherapy, Clin Radiol, 38, 587, 10.1016/S0009-9260(87)80331-8

Habra, 2013, A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma, J Clin Endocrinol Metab, 98, 192, 10.1210/jc.2012-2367

Cohn, 1986, Adrenocortical carcinoma, Surgery, 100, 1170

Bodie, 1989, The Cleveland Clinic experience with adrenal cortical carcinoma, J Urol, 141, 257, 10.1016/S0022-5347(17)40734-8

Kasperlik-Załuska, 1995, Adrenocortical carcinoma. A clinical study and treatment results of 52 patients, Cancer, 75, 2587, 10.1002/1097-0142(19950515)75:10<2587::AID-CNCR2820751028>3.0.CO;2-5

Arriagada, 1996, Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group, J Clin Oncol, 14, 1558, 10.1200/JCO.1996.14.5.1558

Blichert-Toft, 1992, Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group, J Natl Cancer Inst, 19

Fisher, 2002, Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer, N Engl J Med, 347, 1233, 10.1056/NEJMoa022152

Johansen, 2008, Extended radical mastectomy versus simple mastectomy followed by radiotherapy in primary breast cancer. A fifty-year follow-up to the Copenhagen Breast Cancer randomised study, Acta Oncol, 47, 633, 10.1080/02841860801989753

Kuban, 2008, Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer, Int J Radiat Oncol Biol Phys, 70, 67, 10.1016/j.ijrobp.2007.06.054

Poggi, 2003, Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial, Cancer, 98, 697, 10.1002/cncr.11580

van Dongen, 2000, Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial, J Natl Cancer Inst, 92, 1143, 10.1093/jnci/92.14.1143

Veronesi, 2002, Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer, N Engl J Med, 347, 1227, 10.1056/NEJMoa020989

Zietman, 2005, Comparison of Conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial, JAMA, 294, 1233, 10.1001/jama.294.10.1233

King, 1979, Adrenal cortical carcinoma: a clinical and pathologic study of 49 cases, Cancer, 44, 239, 10.1002/1097-0142(197907)44:1<239::AID-CNCR2820440139>3.0.CO;2-R

Ripley, 2011, Liver resection and ablation for metastatic adrenocortical carcinoma, Ann Surg Oncol, 18, 1972, 10.1245/s10434-011-1564-z

Bauditz, 2009, Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer–a case report and review of the literature, Exp Clin Endocrinol Diabetes, 117, 316, 10.1055/s-0028-1087178

Li, 2005, Extended survival in a patient with recurrent and metastatic adrenal cortical carcinoma by aggressive transarterial embolization–a case report, J Surg Oncol, 90, 101, 10.1002/jso.20247

Soga, 2009, A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization, Urol Int, 82, 222, 10.1159/000200804

Thacker, 2009, Embolization of nonliver visceral tumors, Semin Intervent Radiol, 26, 262, 10.1055/s-0029-1225667

de Baere, 2010, Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization, Ann Surg Oncol, 17, 2081, 10.1245/s10434-010-0979-2

Gonzalez, 2009, Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations, J Clin Oncol, 27, 1250, 10.1200/JCO.2008.16.6959

Schussheim, 2001, Multiple endocrine neoplasia type 1: new clinical and basic findings, Trends Endocrinol Metab, 12, 173, 10.1016/S1043-2760(00)00372-6

Higurashi, 1980, The birth prevalence of malformation syndromes in Tokyo infants: a survey of 14,430 newborn infants, Am J Med Genet, 6, 189, 10.1002/ajmg.1320060303

Thorburn, 1970, Exomphalos-macroglossia-gigantism syndrome in Jamaican infants, Am J Dis Child, 119, 316

Weksberg, 2010, Beckwith-Wiedemann syndrome, Eur J Hum Genet, 18, 8, 10.1038/ejhg.2009.106

Bülow, 1996, The incidence rate of familial adenomatous polyposis. Results from the Danish Polyposis Register, Int J Colorectal Dis, 11, 88, 10.1007/BF00342466

Burn, 1991, The UK Northern region genetic register for familial adenomatous polyposis coli: use of age of onset, congenital hypertrophy of the retinal pigment epithelium, and DNA markers in risk calculations, J Med Genet, 28, 289, 10.1136/jmg.28.5.289

Järvinen, 1992, Epidemiology of familial adenomatous polyposis in Finland: impact of family screening on the colorectal cancer rate and survival, Gut, 33, 357, 10.1136/gut.33.3.357

Lammert, 2005, Prevalence of neurofibromatosis 1 in German children at elementary school enrollment, Arch Dermatol, 141, 71, 10.1001/archderm.141.1.71

Rasmussen, 2000, NF1 gene and neurofibromatosis 1, Am J Epidemiol, 151, 33, 10.1093/oxfordjournals.aje.a010118

Stratakis CA , HorvathA. Carney complex. In: PagonRABT, DolanCR, . eds. GeneReviews. Seattle, WA: University of Washington; 2003. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1286/.

Vassilopoulou-Sellin, 1993, Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer, Cancer, 71, 3119, 10.1002/1097-0142(19930515)71:10<3119::AID-CNCR2820711037>3.0.CO;2-8

Barzon, 1997, Adrenocortical carcinoma: experience in 45 patients, Oncology, 54, 490, 10.1159/000227608

van Slooten, 1984, The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring, Eur J Cancer Clin Oncol, 20, 47, 10.1016/0277-5379(84)90033-6

Decker, 1991, Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma, Surgery, 110, 1006

Williamson, 2000, Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study, Cancer, 88, 1159, 10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R

Baudin, 2001, Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma, Cancer, 92, 1385, 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2

van Slooten, 1983, CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma, Cancer Treat Rep, 67, 377

Schlumberger, 1991, 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma, Cancer, 67, 2997, 10.1002/1097-0142(19910615)67:12<2997::AID-CNCR2820671211>3.0.CO;2-#

Burgess, 1993, Chemotherapy with cis-platinum and etoposide (VP-16) for patients with advanced adrenal cortical carcinoma, Proc Am Soc Clin Oncol, 12, 188

Bukowski, 1993, Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study, J Clin Oncol, 11, 161, 10.1200/JCO.1993.11.1.161

Bonacci, 1998, Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma, Br J Cancer, 78, 546, 10.1038/bjc.1998.530

Berruti, 1998, Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer, Cancer, 83, 2194, 10.1002/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3

Khan, 2000, Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use, Ann Oncol, 11, 1281, 10.1023/A:1008377915129

Abraham, 2002, A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist, Cancer, 94, 2333, 10.1002/cncr.10487

Baudin, 2002, Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma, Ann Oncol, 13, 1806, 10.1093/annonc/mdf291

Khan, 2004, Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenocortical cancer, Med Oncol, 21, 167, 10.1385/MO:21:2:167

Berruti, 2005, Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial, Endocr Relat Cancer, 12, 657, 10.1677/erc.1.01025

Sperone, 2010, Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study, Endocr Relat Cancer, 17, 445, 10.1677/ERC-09-0281

Fassnacht, 2012, Combination chemotherapy in advanced adrenocortical carcinoma, N Engl J Med, 366, 2189, 10.1056/NEJMoa1200966

Rustin, 2003, Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results, J Clin Oncol, 21, 2815, 10.1200/JCO.2003.05.185

Shah, 2005, A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol, Clin Cancer Res, 11, 3836, 10.1158/1078-0432.CCR-04-2651

Gross, 2006, The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R, Endocr Relat Cancer, 13, 535, 10.1677/erc.1.01124

Quinkler, 2008, Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine, J Clin Endocrinol Metab, 93, 2057, 10.1210/jc.2007-2564

Hong, 2009, Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies, Clin Cancer Res, 15, 7061, 10.1158/1078-0432.CCR-09-1241

Berruti, 2012, Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma, Eur J Endocrinol, 166, 451, 10.1530/EJE-11-0918